HS
TIL icon

HighVista Strategies’s Instil Bio TIL Stock Holding History

HighVista Strategies’s Portfolio TIL Stock Details TIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,845
Closed -$974K – 100
2021
Q4 		$974K Sell
2,845
-759
-21% -$293K 0.78% 48
2021
Q3 		$1.29M Buy
3,604
+1,532
+74% +$572K 0.85% 30
2021
Q2 		$801K Buy
+2,072
New +$768K 0.57% 47

Other funds holding TIL

CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

HighVista Strategies's TIL Position: Q1 2022 in Review

HighVista Strategies sold out of Instil Bio (TIL) in Q1 2022, closing a stake of 2,845 shares — an estimated $974K sold.

HighVista Strategies first reported a position in TIL in Q2 2021 and held it in 3 quarters. The position peaked at $1.29M in Q3 2021. 78 funds tracked by Wall St. Rank hold TIL as of Q1 2022.

  • HighVista Strategies reported no remaining Instil Bio position as of Q1 2022 after selling out during the quarter.
  • HighVista Strategies sold 2,845 Instil Bio shares in Q1 2022, an estimated $974K.
  • HighVista Strategies first reported a position in Instil Bio in Q2 2021 and held it in 3 quarters.
  • HighVista Strategies's Instil Bio position peaked at $1.29M in Q3 2021.
  • 78 funds tracked by Wall St. Rank held Instil Bio as of Q1 2022.

Based on HighVista Strategies's 13F filing for Q1 2022, filed 16 May 2022.